AXIM · Axim Biotechnologies, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $17.5K | $53.0K | - | $9.6K | $9.9K | $7.4K | - | $1.3K | $0 | $0 |
| Cost of Revenue | $1.7K | - | - | - | - | - | - | - | - | - |
| Gross Profit | $15.7K | - | - | - | - | - | - | $1.3K | - | - |
| R&D | $4.1K | $15.5K | - | $34.7K | $34.1K | $20.3K | - | $29.7K | $35.2K | $44.2K |
| SG&A | $473.0K | $333.8K | - | $456.6K | $566.8K | $590.9K | - | $1.18M | $918.7K | $982.2K |
| Total Operating Expenses | $585.2K | $457.3K | - | $598.1K | $707.7K | $718.0K | - | $1.32M | $1.06M | $1.13M |
| D&A | $108.1K | $108.0K | - | $106.8K | $106.8K | $106.8K | - | $6.9K | $6.8K | $106.5K |
| Operating Income | ($569.4K) | ($404.4K) | - | ($588.5K) | ($697.7K) | ($710.6K) | - | ($1.32M) | ($1.06M) | ($1.13M) |
| Interest Expense | $751.5K | $163.6K | - | $64.7K | $35.0K | $57.8K | - | $57.5K | $60.2K | $1.52M |
| Income Tax | $0 | $0 | - | $0 | - | $0 | - | $0 | $0 | $0 |
| Net Income | ($2.27M) | ($292.3K) | - | $328.5K | ($3.72M) | ($2.76M) | - | ($2.03M) | ($1.22M) | ($2.09M) |
| EPS - Basic | ($0.01) | ($0.00) | - | $0.00 | ($0.02) | ($0.01) | - | ($0.01) | ($0.01) | ($0.01) |
| EPS - Diluted | ($0.01) | ($0.00) | - | $0.00 | ($0.02) | ($0.01) | - | ($0.01) | ($0.01) | ($0.01) |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.0K | $96.7K | $156.5K | $23.2K | $97.5K | $53.5K | $47.3K | $163.7K | $65.2K | $408.0K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | $20.1K | $20.1K | $20.1K |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $20.2K | $96.7K | $156.5K | $23.2K | $97.5K | $56.6K | $104.0K | $249.2K | $173.2K | $497.9K |
| Total Assets | $3.73M | $3.93M | $4.12M | $4.04M | $4.25M | $4.04M | $4.21M | $4.48M | $4.52M | $5.06M |
| Current Liabilities | $6.57M | $4.80M | $5.98M | $4.28M | $8.37M | $4.86M | $3.39M | $3.16M | $2.71M | $3.36M |
| Long-term Debt | $4.89M | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $13.26M | $11.38M | $11.78M | $10.00M | $14.00M | $10.20M | $9.04M | $8.86M | $8.25M | $8.49M |
| Stockholders' Equity | ($9.53M) | ($7.45M) | ($7.66M) | ($5.96M) | ($9.75M) | ($6.16M) | ($4.83M) | ($4.38M) | ($3.73M) | ($3.42M) |
| Retained Earnings | ($74.75M) | ($72.48M) | ($72.18M) | ($70.28M) | ($70.61M) | ($66.89M) | ($64.13M) | ($63.23M) | ($61.19M) | ($59.97M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($1.07M) | - | - | - | ($142.0K) | - | - | - | ($703.7K) |
| Investing Cash Flow | - | ($2.8K) | - | - | - | $0 | - | - | - | $0 |
| Financing Cash Flow | - | $1.01M | - | - | - | $148.2K | - | - | - | $658.8K |
| CapEx | - | $2.8K | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | ($1.07M) | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 90.0% | - | - | - | - | - | - | 100.0% | - | - |
| Operating margin | -3257.9% | -763.3% | - | -6142.7% | -7027.2% | -9607.1% | - | -100298.3% | - | - |
| EBITDA margin | -2639.2% | -559.4% | - | -5028.5% | -5952.0% | -8163.8% | - | -99770.5% | - | - |
| Net margin | -12986.0% | -551.7% | - | 3428.3% | -37499.2% | -37348.0% | - | -154836.1% | - | - |
| Free cash flow margin | - | -2019.5% | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 3.66 | - | - | - | - | - | - | - | - |
| R&D / Revenue | 23.2% | 29.2% | - | 362.3% | 343.2% | 274.9% | - | 2261.9% | - | - |
| SG&A / Revenue | 2706.0% | 630.1% | - | 4766.2% | 5708.8% | 7988.9% | - | 90012.8% | - | - |
| Effective tax rate | - | - | - | 0.0% | - | - | - | - | - | - |
| Return on assets | -60.9% | -7.4% | - | 8.1% | -87.7% | -68.3% | - | -45.4% | -27.0% | -41.2% |
| Return on equity | 23.8% | 3.9% | - | -5.5% | 38.2% | 44.8% | - | 46.4% | 32.8% | 60.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.00 | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | 0.08 | 0.06 | 0.15 |
| Quick ratio | 0.00 | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 | 0.03 | 0.07 | 0.06 | 0.14 |
| Cash ratio | 0.00 | 0.02 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 | 0.02 | 0.12 |
| Leverage | ||||||||||
| Debt / Equity | -0.51 | - | - | - | - | - | - | - | - | - |
| Debt / Assets | 1.31 | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -0.8x | -2.5x | - | -9.1x | -19.9x | -12.3x | - | -22.9x | -17.6x | -0.7x |
| Equity multiplier | -0.39 | -0.53 | -0.54 | -0.68 | -0.44 | -0.66 | -0.87 | -1.02 | -1.21 | -1.48 |
| Liabilities / Assets | 3.56 | 2.89 | 2.86 | 2.47 | 3.30 | 2.52 | 2.15 | 1.98 | 1.83 | 1.68 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | 0.01 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | 30.0x | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | 1048.8x | 499.4x | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 76.0% | 616.2% | - | 629.1% | - | - | - | -83.8% | -100.0% | -100.0% |
| Revenue CAGR (3y) | 5.5% | 17.5% | - | - | - | 1.2% | - | -85.2% | - | - |
| Revenue CAGR (5y) | -28.4% | 25.4% | - | 9.0% | 4.0% | -12.3% | - | -33.0% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 18.4% | 43.1% | - | 55.3% | 34.2% | 37.3% | - | 59.8% | 51.4% | -30.5% |
| Net income growth (YoY) | 39.0% | 89.4% | - | - | -204.5% | -32.4% | - | 38.2% | 68.1% | -141.4% |
| EPS growth (YoY) | 50.0% | 90.0% | - | - | -100.0% | 0.0% | - | 50.0% | 66.7% | 66.7% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 2.2% | -20.9% | -58.7% | -35.9% | -161.2% | -80.0% | -106.4% | - | -932.1% | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing AXIM BIOTECHNOLOGIES against the 5 most active filers in the same SIC group.